| Family: | Van Eck Associates Corporation |
| Name: | VanEck Pharmaceutical ETF |
| Inception Date: | 20-Dec-2011 |
| Termination Date: | |
| Investment Objective: | The Market Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. The Index is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies. |
| Prospectus | |
| Top 10 Holdings | ||
| Eli Lilly & Co | LLY | 24.2566% |
| Novartis Ag | NVS | 9.1367% |
| Merck & Co Inc | MRK | 7.8392% |
| Novo Nordisk A/S | NVO | 5.9374% |
| Gsk Plc | GSK | 4.7546% |
| Johnson & Johnson | JNJ | 4.7299% |
| Mckesson Corp | MCK | 4.5168% |
| Bristol-Myers Squibb Co | BMY | 4.4901% |
| Pfizer Inc | PFE | 4.4766% |
| Astrazeneca Plc | AZN | 4.3960% |
| Top 10 Holdings Weight: | 74.5% |
| Number of Holdings: | 27 |
| Shares Outstanding: | 11,338,138 |
| Total Net Assets: | 1,145,152,000 |
| NAV: | 100.97 |
| Net Expense Ratio: | 0.36% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Pharmaceuticals |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Global |
